Meeting
2022 ASCO Gastrointestinal Cancers Symposium
PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.
Authors
Melissa Amy Lumish
Memorial Sloan Kettering Cancer Center, New York, NY
Melissa Amy Lumish , Jenna L. Cohen , Zsofia Kinga Stadler , Jill A Weiss , Michelle F. Lamendola-Essel , Rona Yaeger , Neil Howard Segal , Imane H. El Dika , Leonard B. Saltz , Marina Shcherba , Ryan Sugarman , Avni Mukund Desai , Jesse Joshua Smith , Maria Widmar , Emmanouil Pappou , Philip Paty , Julio Garcia-Aguilar , Martin R. Weiser , Luis A. Diaz Jr., Andrea Cercek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04165772
DOI
10.1200/JCO.2022.40.4_suppl.016
Abstract #
16
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.
First Author: Thierry Andre
Poster
2020 Gastrointestinal Cancers Symposium
Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.
First Author: Thierry Andre
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
First Author: Pashtoon Murtaza Kasi
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko